Clinical Trials

TAC T-cells for the Treatment of HER2-positive Solid Tumors (TACTIC-2)

TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T-cells expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2). TAC directs T-cells to the targeted antigen (HER2), and once engaged with the target, activates them via the endogenous T-cell receptor. This is an open-label, multicenter Phase 1/2 study that aims to establish safety, Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (RP2D), pharmacokinetic profile and efficacy of TAC01-HER2 in subjects with relapsed or refractory solid tumors.

Contact us for more information on our trials.

    Read the Complete Clinical Trial Brief at

    A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC-T Cells
    Targeting HER2 in Relapsed or Refractory Solid Tumors (TACTIC-2)

    Dose Escalation Phase

    Indications: HER2+ Solid Tumors

    Status: Phase I Enrollment Complete

    Locations: Princess Margaret Cancer Center in Toronto, Canada

    Dose Expansion Phase

    Indication: HER2+ Solid Tumors

    Status: Recruiting Projected to Open October 2023

    Locations: Dana Farber Cancer Institute in Boston, Massachusetts

    University of Chicago Medical Center in Chicago, Illinois

    MD Anderson Cancer Center in Houston, Texas

    Princess Margaret Cancer Center in Toronto, Canada